- Home
- NERV vs VCIG Comparison
NERV vs VCIG Comparison
Compare NERV & VCIG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NERV
- VCIG
- Stock Information
- Founded
- NERV 2007
- VCIG 2013
- Country
- NERV United States
- VCIG Malaysia
- Employees
- NERV N/A
- VCIG N/A
- Industry
- NERV Biotechnology: Pharmaceutical Preparations
- VCIG Diversified Commercial Services
- Sector
- NERV Health Care
- VCIG Consumer Discretionary
- Exchange
- NERV Nasdaq
- VCIG Nasdaq
- Market Cap
- NERV 12.6M
- VCIG 10.2M
- IPO Year
- NERV 2014
- VCIG 2023
- Fundamental
- Price
- NERV $1.73
- VCIG $1.84
- Analyst Decision
- NERV Hold
- VCIG
- Analyst Count
- NERV 1
- VCIG 0
- Target Price
- NERV $5.00
- VCIG N/A
- AVG Volume (30 Days)
- NERV 12.1K
- VCIG 2.1M
- Earning Date
- NERV 08-05-2025
- VCIG 08-18-2025
- Dividend Yield
- NERV N/A
- VCIG N/A
- EPS Growth
- NERV N/A
- VCIG N/A
- EPS
- NERV 0.83
- VCIG 54.73
- Revenue
- NERV N/A
- VCIG $27,819,290.00
- Revenue This Year
- NERV N/A
- VCIG N/A
- Revenue Next Year
- NERV N/A
- VCIG N/A
- P/E Ratio
- NERV $2.06
- VCIG $0.04
- Revenue Growth
- NERV N/A
- VCIG 36.99
- 52 Week Low
- NERV $1.15
- VCIG $1.67
- 52 Week High
- NERV $3.50
- VCIG $607.50
- Technical
- Relative Strength Index (RSI)
- NERV 50.22
- VCIG 33.32
- Support Level
- NERV $1.57
- VCIG $2.05
- Resistance Level
- NERV $1.88
- VCIG $2.45
- Average True Range (ATR)
- NERV 0.09
- VCIG 0.29
- MACD
- NERV -0.02
- VCIG 0.00
- Stochastic Oscillator
- NERV 52.03
- VCIG 10.96
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
About VCIG VCI Global Limited
VCI Global Ltd is a holding company. The principal activities of the Company and its subsidiaries are the provision of business Strategy consultancy and technology development. The firm organized its consulting services into three main segments: Business Strategy Consultancy; Technology development, solutions and consultancy; and Others. It derives the majority of its revenue from the Business Strategy Consultancy segment, which focuses on listing solutions, investor relations, and boardroom strategies consultancy.